<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) who were anemic and/or thrombocytopenic were treated with <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> (5-AZA) at a dose of 75 mg/m(2) per day SQ x 7 days </plain></SENT>
<SENT sid="1" pm="."><plain>This cycle was repeated every 28 days </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-eight patients who received at least one cycle of 5-AZA were evaluable for response </plain></SENT>
<SENT sid="3" pm="."><plain>Hematological toxicity was mild and consisted of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and <z:hpo ids='HP_0001882'>leukopenia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Extramedullary toxicity was uncommon and consisted of <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, <z:hpo ids='HP_0002829'>arthralgia</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and injection site irritation </plain></SENT>
<SENT sid="5" pm="."><plain>Eighteen of the 46 transfusion dependent patients became transfusion independent (39%) </plain></SENT>
<SENT sid="6" pm="."><plain>Median duration of response was 7 months with three patients continuing beyond 2 years </plain></SENT>
<SENT sid="7" pm="."><plain>French Anglo British (FAB) classification and the International Scoring System (ISS) did not predict response to 5-AZA </plain></SENT>
<SENT sid="8" pm="."><plain>However, a decrease in the white blood cells (WBC) during the initial cycle of 5-AZA correlated with a higher response rate </plain></SENT>
</text></document>